Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:28:48 EDT Tue 09 Jun 2026
Enter Symbol
or Name
USA
CA



Q:AMGN - AMGEN INC - https://www.amgen.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AMGN - Q0.1344.82·345.150.6344.90-0.83-0.2484.9166,42310,799348.24  349.64  342.6201391.29  267.8311:08:00Jun 0715 min RT 2¢

Recent Trades - Last 10 of 10799
Time ETExPriceChangeVolume
11:08:08Q344.86-0.8716
11:08:06Q344.9596-0.77042
11:08:06Q344.866-0.8649
11:08:06Q344.86-0.8731
11:08:05Q344.86-0.872
11:08:05Q344.86-0.872
11:08:01Q344.89-0.8425
11:08:01Q344.89-0.8415
11:08:01Q344.8201-0.90991
11:08:00Q344.9701-0.75991

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-06-07 16:45U:AMGNNews ReleaseAMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
2026-06-04 16:01U:AMGNNews ReleaseAMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
2026-06-03 09:00U:AMGNNews ReleaseAMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
2026-05-29 16:01U:AMGNNews ReleaseAMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
2026-05-27 09:00U:AMGNNews ReleaseEmber LifeSciences announces new strategic investments boosting Series A to $27M
2026-05-19 16:05U:AMGNNews ReleaseAMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH
2026-05-13 08:30U:AMGNNews ReleaseCNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
2026-05-11 08:30U:AMGNNews ReleaseThe Next Generation of the GLP-1 Revolution Is Already Underway
2026-05-07 16:01U:AMGNNews ReleaseAMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
2026-05-04 09:00U:AMGNNews ReleaseAMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR
2026-04-30 19:02U:AMGNNews Release/C O R R E C T I O N -- Amgen/
2026-04-30 16:01U:AMGNNews ReleaseAMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
2026-04-24 16:01U:AMGNNews ReleaseAMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS
2026-04-22 16:00U:AMGNNews ReleaseAMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
2026-04-06 09:00U:AMGNNews ReleaseAMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA(TM) IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
2026-03-28 16:45U:AMGNNews ReleaseREPATHA(TM) CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
2026-03-05 16:01U:AMGNNews ReleaseAMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
2026-03-04 16:01U:AMGNNews ReleaseAMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
2026-02-24 16:01U:AMGNNews ReleaseAMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
2026-02-13 16:01U:AMGNNews ReleaseAMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT